Atlas Trials

A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM

Clinical trial NCT02766699 · COMPLETED

Trial details

NCT number
NCT02766699
Sponsor
Engeneic Pty Limited
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
GlioblastomaAstrocytoma, Grade IV
Start date
2016-10-25
Primary completion
2021-08-21
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.